GLP-1 Weight Loss Plateau: What Trials Show (Philippines)

Why does weight loss on GLP-1 medicines stall? Filipinos researching these drugs ask it often. A plateau is when the weight curve flattens. In the big trials, every curve does it.

In semaglutide's STEP trials, weight loss appeared to plateau around week 60. A 2025 analysis of SURMOUNT-1 found about nine in ten people on tirzepatide had reached a plateau by week 72. Why? The first named mechanism is metabolic adaptation.

A smaller body burns less energy, sometimes even less than predicted. In a 2016 study of 14 contestants from a televised weight-loss competition, resting metabolism was still about 500 calories a day below predicted, six years later. Appetite pushes back too. In a 2011 diet study of 50 adults, leptin stayed lower and hunger stayed higher one year after weight loss.

So what happens after stopping? In the STEP 1 extension, published in 2022, people who stopped semaglutide regained about two-thirds of their lost weight within a year. In SURMOUNT-4, published in 2023, adults who switched to placebo regained 14 percent of body weight over the next year. Those who continued lost another 5.

5 percent. Long-term maintenance is still being studied. Tirzepatide is now a prescription medicine in Philippine drugstores, and research vials are not approved medicines. If you are sourcing research peptides in Metro Manila or the provinces, Primara Labs publishes independent lab reports you can verify yourself.

Guides at primaralabs.com.